Growth-hormone secretagogues
Peptides that prompt the pituitary to release growth hormone, via two distinct pathways: GHRH analogs and ghrelin-receptor agonists.
How this class works
GHRH analogs activate the GHRH receptor; ghrelin-receptor (GH-secretagogue receptor) agonists act through a separate pathway. Both increase pulsatile growth-hormone release rather than supplying GH directly.
Tesamorelin grades highest (A-tier) on current published evidence; approved members: Tesamorelin. This reflects evidence maturity — not a recommendation to use anything.
Compounds in this class
Head-to-head: Tesamorelin vs Sermorelin
FAQ
Which growth-hormone secretagogues has the strongest evidence?
Tesamorelin currently grades highest in this class (A-tier) on published evidence — which reflects evidence maturity, not a recommendation.
Are any growth-hormone secretagogues FDA-approved?
Yes — Tesamorelin is FDA-approved for specific indications. Others in the class are investigational or research-only.
How do compounds in this class differ?
GHRH analogs activate the GHRH receptor; ghrelin-receptor (GH-secretagogue receptor) agonists act through a separate pathway. Both increase pulsatile growth-hormone release rather than supplying GH directly. Within the class, members differ widely in evidence maturity, approval status, and safety — the tiers and evidence stages above show how.
Research reference only. Not medical advice. Compounds in a class can differ greatly in evidence, approval status, and safety.